IQV

IQVIA Holdings Inc. operates behind the scenes, running clinical trials and processing vast healthcare data for pharmaceutical companies. IQV's business spans clinical trial management, healthcare data analytics, software products, and consulting, providing diversified revenue streams. I previously rated IQV a Buy due to strong results and robust demand, but concerns over slowing guidance, CSMS segment weakness, and regulatory risks tempered my enthusiasm.

The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

IQVIA NYSE: IQV reported second-quarter results that exceeded the high end of its guidance, supported by accelerating organic revenue growth, higher R&D Solutions bookings and operational productivity gains. The company also raised its full-year outlook for revenue, adjusted EBITDA and adjusted diluted earnings per share.

IQVIA Holdings leads the index after the company boosted its full-year outlook on the back of a strong second quarter.

IQVIA's Q2 earnings beat estimates as record R&D bookings, broad-based growth and stronger demand support a raised 2026 outlook.

IQVIA Holdings (IQV) came out with quarterly earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.02 per share. This compares to earnings of $2.81 per share a year ago.

IQVIA Holdings raised its annual profit forecast on Tuesday after reporting better-than-expected second-quarter results, driven by strong ​demand for its healthcare data and analytics services, ‌sending its shares up 11% before the bell.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended June 30, 2026. Year-Over-Year Comparisons As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model to strengthen collaboration, enhance efficien.

IQV heads into its Q2'26 earnings release with y/y revenue and EPS growth expected, supported by AI adoption, drug launches and high-margin segment gains.

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.